AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04463043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfBACK app
Description: The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
Study NCT04463043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Help webpage
Description: The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
Study NCT04463043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care refers to seeking care or receiving treatments or help as usual.
Study NCT04463043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to seeking care or receiving treatments or help as usual.
Study NCT03717545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb
Study NCT02334943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test
Study NCT02243072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit Families plus Standard Medical Care
Description: Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
Study NCT00502281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified urinary FSH
Study NCT02910583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
Study NCT01737619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT01737619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given via superficial and deep cervical injection
Study NCT01737619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02910583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules to match ibrutinib administered orally once daily
Study NCT01737619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymph node mapping
Study NCT01737619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo full lymphadenectomy
Study NCT01737619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT00502281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timed intercourses, intrauterine insemination
Study NCT04011384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic intervention of online purchasing at a food pantry
Description: This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
Study NCT04361747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nursing counseling
Description: The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
Study NCT01060566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
Study NCT01060566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
Study NCT01169519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.125mg/kg injection over 20min
Study NCT01169519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.25mg/kg injection over 20min
Study NCT01169519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.35mg/kg by injection over 20min
Study NCT01169519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil by injection
Description: Sildenafil 0.45mg/kg by injection over 20min
Study NCT00852475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MUFA MOVE! (Monounsaturated fatty enriched diet)
Description: MUFA MOVE!diet and exercise program
Study NCT00852475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
Description: PUFA MOVE! diet and exercise program
Study NCT00594932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
Study NCT00594932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months.
Study NCT04478747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVM
Description: Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
Study NCT04478747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
Study NCT00480441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: 10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
Study NCT00480441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BRENDA therapy
Description: weekly therapy sessions for 6 weeks
Study NCT00480441 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA therapy
Description: weekly therapy sessions for 6 weeks
Study NCT00480441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules daily for 2 weeks followed by a 1 week taper
Study NCT02974309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
Study NCT02974309 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Routine
Description: All youth in this condition are asked to follow the routines set by their clinical care team.
Study NCT04482478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract of Dolichos lablab Linne (EDL)
Description: Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
Study NCT04482478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo: consumed in the same way as the investigational product
Study NCT01706692 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: BIOLOGICAL
Intervention: Etanercept
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ustekinumab
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: DRUG
Intervention: Cyclosporine A
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: DRUG
Intervention: Fumaric acids
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: all dosages, frequencies and durations prescribed
Study NCT01706692 — intervention group
Intervention type: DRUG
Intervention: Other anti-psoriatic systemic treatments
Description: all dosages, frequencies and durations prescribed
Study NCT02978560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fluorescence-mediated photoplethysmography
Description: Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
Study NCT02696993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT02696993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02696993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02696993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02785601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride prolonged-release tablets
Description: strength 75mg, 150 mg. Oral administration with 200ml water
Study NCT02696993 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT02696993 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT01687270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study NCT01687270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
Study NCT04808869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
Study NCT04808869 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
Study NCT05930899 — intervention group
Intervention type: OTHER
Intervention: Genetics
Description: TOmAS is a biobank and all patients will be genotyped
Study NCT03358147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 7.2 μg
Description: GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
Study NCT03358147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo taken as 2 inhalations BID
Study NCT02179918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Starting dose of 0.45 mg/kg q3wks IV, dose escalation
Study NCT02179918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 2 mg/kg q3wks, IV
Study NCT01385176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implant of investigational device system
Description: Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
Study NCT01615627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HypotonicTreprostinil Solution
Description: Hypotonic Treprostinil Solution
Study NCT01615627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eutonic Treprostinil Solution
Description: Eutonic Treprostinil Solution
Study NCT04866342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study NCT04866342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study NCT03801772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metronome
Description: Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
Study NCT01385176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of investigational device system
Description: Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
Study NCT01385176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration during the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
Study NCT01385176 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Titration after the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
Study NCT01385176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration after the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
Study NCT01385176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Draw
Description: Blood draw before implant and 6 months after implant at the end of the randomization phase.
Study NCT01385176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood draw before implant and 6 months after implant at the end of the randomization phase.
Study NCT03358147 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Spiriva Respimat 2.5 μg
Description: Spiriva Respimat 2.5 μg QD (open-label)
Study NCT05100680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomp
Description: Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
Study NCT05100680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
Study NCT00988468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
Study NCT00988468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
Study NCT00988468 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video Observation
Description: Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
Study NCT03542734 — intervention group
Intervention type: OTHER
Intervention: multimodal magnetic resonance imaging
Description: multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
Study NCT03099681 — intervention group
Intervention type: OTHER
Intervention: Treatment for Epitheloid Sarcoma
Description: Treatment Epitheloid Sarcoma according the disease guideline
Study NCT02787369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Study NCT02787369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT02787369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Study NCT00846742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanford V Chemotherapy
Description: The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
Study NCT00846742 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
Study NCT01364675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin+Enalapril+Simvastatin
Description: Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
Study NCT01364675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Identical Placebo Tablet
Study NCT01678027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
Study NCT01678027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAC triple therapy
Description: Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
Study NCT04510974 — intervention group
Intervention type: OTHER
Intervention: Spinal Cord Injury
Description: Spinal Cord Injury
Study NCT02923427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask Supreme Evaluation
Description: Evaluation of clinical performance in terms of Insertion, ventilation and complications
Study NCT02923427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel Evaluation
Description: Evaluation of clinical performance in terms of Insertion,ventilation and complications
Study NCT00145600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 Week Stanford V Chemotherapy
Description: 12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children